For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Jones Lab

Publications

Found 54 results
2021
Kinloch NN, Ren Y, Alberto WDConce, Dong W, Khadka P, Huang SHan, Mota TM, Wilson A, Shahid A, Kirkby D et al..  2021.  HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA).. Nat Commun. 12(1):165.
Stevenson EM, Ward AR, Truong R, Thomas AS, Huang S-H, Dilling TR, Terry S, Bui JK, Mota TM, Danesh A et al..  2021.  HIV-specific T-cell responses reflect substantive in vivo interactions with antigen despite long-term therapy.. JCI Insight.
2020
Ren Y, Huang SHan, Patel S, Alberto WDConce, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E et al..  2020.  BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.. J Clin Invest. 130(5):2542-2559.
Patel S, Hanajiri R, Grant M, Saunders D, Van Pelt S, Keller M, Hanley PJ, Simon G, Nixon DF, Hardy D et al..  2020.  HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform.. Mol Ther Methods Clin Dev. 16:11-20.
Mota TM, McCann CD, Danesh A, Huang S-H, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM et al..  2020.  Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8 T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.. J Virol. 94(9)
Danesh A, Ren Y, R Jones B.  2020.  Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.. Curr Opin HIV AIDS. 15(5):316-323.
2019
R Jones B.  2019.  Current challenges and recent advances in the search for a cure for HIV.. J Int AIDS Soc. 22(2):e25248.
Flerin NC, Bardhi A, Zheng JHua, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E et al..  2019.  Establishment of a Novel Humanized Mouse Model To Investigate Activation and Depletion of Patient-Derived HIV Latent Reservoirs.. J Virol. 93(6)
Huang S-H, McCann CD, Mota TM, Wang C, Lipkin SM, R Jones B.  2019.  Have Cells Harboring the HIV Reservoir Been Immunoedited? Front Immunol. 10:1842.
Mota TM, R Jones B.  2019.  HTLV-1 as a Model for Virus and Host Coordinated Immunoediting.. Front Immunol. 10:2259.
2018
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang S-H, Ren Y, Spivak AM, Jones RB, Planelles V et al..  2018.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.. JCI Insight. 3(19)
Osuna CE, Lim S-Y, Kublin JL, Apps R, Chen E, Mota TM, Huang S-H, Ren Y, Bachtel ND, Tsibris AM et al..  2018.  Evidence that CD32a does not mark the HIV-1 latent reservoir.. Nature. 561(7723):E20-E28.
Huang S-H, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CRussell, Karandish S et al..  2018.  Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.. J Clin Invest. 128(2):876-889.
Ren Y, Korom M, Truong R, Chan D, Huang S-H, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H et al..  2018.  Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.. J Virol.
2016
R Jones B, Walker BD.  2016.  HIV-specific CD8⁺ T cells and HIV eradication.. J Clin Invest. 126(2):455-63.
2015
Brockman MA, R Jones B, Brumme ZL.  2015.  Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs.. Front Immunol. 6:506.
Huang Z, Cai L, Tu BP.  2015.  Dietary control of chromatin.. Curr Opin Cell Biol. 34:69-74.
Anmole G, Kuang XT, Toyoda M, Martin E, Shahid A, Le AQ, Markle T, Baraki B, R Jones B, Ostrowski MA et al..  2015.  A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion.. J Immunol Methods. 426:104-13.
2014
Gupta R, Michaud H-A, Zeng X, Debbaneh M, Arron ST, Jones RB, Ormsby CE, Nixon DF, Liao W.  2014.  Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis.. J Transl Med. 12:256.
Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A et al..  2014.  Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.. PLoS Pathog. 10(8):e1004287.
Sheppard NC, Jones RB, Burwitz BJ, Nimityongskul FA, Newman LP, Buechler MB, Reed JS, Piaskowski SM, Weisgrau KL, Castrovinci PA et al..  2014.  Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication.. PLoS One. 9(3):e92012.
2013
Ndhlovu ZM, Chibnik LB, Proudfoot J, Vine S, McMullen A, Cesa K, Porichis F, Jones RB, Alvino DMarie, Hart MG et al..  2013.  High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control.. Blood. 121(5):801-11.
Jones RB, Leal FE, Hasenkrug AM, Segurado AC, Nixon DF, Ostrowski MA, Kallas EG.  2013.  Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.. J Negat Results Biomed. 12:3.
Jones RB, Song H, Xu Y, Garrison KE, Buzdin AA, Anwar N, Hunter DV, Mujib S, Mihajlovic V, Martin E et al..  2013.  LINE-1 retrotransposable element DNA accumulates in HIV-1-infected cells.. J Virol. 87(24):13307-20.
2012
Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, Benko E, Kovacs C, Ostrowski MA.  2012.  Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway.. J Immunol. 188(8):3745-56.